Fluoxetine and Haloperidol interaction

Fluoxetine and Haloperidol: both prescribing labels describe an interaction that usually calls for monitoring, a dose change, or spacing the doses.

Moderate

Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.

What the FDA labels say

From the Fluoxetine (Prozac) label · effective 2026-01-08

Moderate

Use with caution in combination with other drugs that prolong the QT interval ( 4.2 , 5.11 , 7.7 , 7.8 ) 7.1 Monoamine Oxidase Inhibitors (MAOI) [See Dosage and Administration ( 2.9 , 2.10 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 )] .

Drug interactionsby drug classView label on DailyMed
Moderate

Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6, including certain antidepressants (e.g., TCAs), antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics (e.g., propafenone, flecainide, and others) should be approached with caution.

Drug interactionsby drug classView label on DailyMed
Minor

Elevation of blood levels of haloperidol and clozapine has been observed in patients receiving concomitant fluoxetine.

Drug interactionsnames HaloperidolView label on DailyMed
Minor

These include specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, mesoridazine, droperidol,); specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin); Class 1A antiarrhythmic medications (e.g., quinidine, procainamide); Class III antiarrhythmics (e.g., amiodarone, sotalol); and others (e.g., pentamidine, levomethadyl…

Warnings and precautionsby drug classView label on DailyMed
Minor

Antipsychotics: Potential for elevation of haloperidol and clozapine levels ( 7.7 )

Drug interactionsby drug classView label on DailyMed

From the Haloperidol (Haldol Decanoate) label · effective 2025-11-11

Moderate

Concomitant use of HALDOL DECANOATE with other products that prolong the QTc interval may result in a greater increase in the QTc interval, and adverse reactions associated with QTc interval prolongation, including torsade de pointes, other serious arrythmias, and sudden death [see Warnings and Precautions (5.2) ].

Drug interactionsby drug classView label on DailyMed
Moderate

CYP3A4 and/or CYP2D6 Inhibitors Clinical Impact CYP3A4 and/or CYP2D6 inhibitors increase haloperidol exposure (haloperidol is a CYP3A4 and CYP2D6 substrate) [see Clinical Pharmacology (12.3) ].

Drug interactionsby drug classView label on DailyMed
Moderate

Concomitant use of HALDOL DECANOATE and CYP3A4 and/or CYP2D6 inhibitors may increase the risk of haloperidol-associated adverse reactions.

Drug interactionsby drug classView label on DailyMed
Minor

Table 3: Other Clinically Significant Drugs Interactions See www.fda.gov/CYPandTransporterInteractingDrugs for examples of CYP3A4 and/or CYP2D6 inhibitors, CYP3A4 inducers, and CYP2D6 substrates.

Drug interactionsby drug classView label on DailyMed
Minor

CYP2D6 Substrates Clinical Impact Haloperidol is a CYP2D6 inhibitor.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.